Announced Wed, 6 May · 16:57 IST

Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia, to consider and approve Audited Standalone ....

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.9%1-day move
₹24.72
prior close
₹24.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0-6.1+0.0+0.0-2.9-3.0+0.6+1.9+4.4-1.7-2.9-18.1-22.7
Up moveDown movePending
AI summary

Venmax Drugs and Pharmaceuticals Ltd has informed BSE that its Board meeting is scheduled for May 14, 2026 at 3:30 PM. The meeting will consider and approve the Audited Standalone Financial Results for the quarter and year ended March 31, 2026. The company has also confirmed that the Trading Window remains closed for all Designated Persons from April 1, 2026 until May 16, 2026, which is 48 hours after the approval of the financial results. This is a standard regulatory compliance intimation under SEBI LODR regulations.

Likely market impact

This is a routine filing announcing the upcoming approval of annual financial results. Shareholders should note that trading restrictions are in place until results are disclosed to prevent insider trading.